By: Benzinga
UPDATE: Jefferies Raises PT to $41 on Bristol-Myers Squibb on Long-Term Growth Prospects
Jefferies maintained Bristol-Myers Squibb (NYSE: BMY ) with a Buy rating and raisd the price target from $39.00 to $41.00. Jefferies said, "2013 will likely deliver several major catalysts that will shape the direction of Bristol-Myers' mid to long term growth. We believe that Eliquis will beat launch expectations providing
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here